FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Instagram Outage Disrupts Thousands of U.S. Users 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
BRISBANE, Calif., Nov. 08, 2016 -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Dr. Peter Maag, Chief Executive Officer, and Charles Constanti, Chief Financial Officer, will be participating in four upcoming investor conferences:
Mizuho Global Investor Conference in New York City
- Dr. Peter Maag and Charles Constanti will participate in one-on-one meetings on Monday, November 14, 2016
7th Annual Craig-Hallum Alpha Select Conference in New York City
- Dr. Peter Maag and Charles Constanti will present on Wednesday, November 16, 2016 at 11:50am PT/2:50pm ET.
28th Annual Piper Jaffray Healthcare Conference in New York City
- Dr. Peter Maag and Charles Constanti will present on Tuesday, November 29, 2016 at 11:00am PT/1:00pm ET.
Evercore ISI MedTools Investor Conference in Boston, MA
- Dr. Peter Maag and Charles Constanti will participate in one-on-one meetings on December 1, 2016.
A live audio webcast of the Craig-Hallum Alpha Select and Piper Jaffray Healthcare conferences presentations will be available online from the Investor Relations page of the Company's website at http://investors.caredxinc.com. The webcast replay of each presentation will be available on the Company's website for 90 days. Due to the one-on-one only format of the Mizuho and Evercore ISI MedTools conferences, no webcasts will be available.
About CareDx
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, diagnostic solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying risk of rejection in heart transplant recipients.
CareDx is also pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing, to detect donor-derived cell-free DNA to monitor the health of organs after transplantation. For more information, please visit: www.CareDx.com.
CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. For more information, please visit: www.CareDx.com.
Investor Relations Contact Jamar Ismail, Vice President Westwicke Partners, LLC T: +1 415-513-1282 E: [email protected]
